Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes.
Division of Hematology, Department of Medicine, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan.Leukemia & lymphoma (impact factor: 2.4). 03/2009; 50(2):290-3. DOI:10.1080/10428190802627598 pp.290-3
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.